【三叶草生物-B(02197.HK):RSV候选疫苗SCB-1019获美国IND临床试验批准并启动重复接种的临床研究】三叶草生物-B(02197.HK)发布公告,公司RSV候选疫苗SCB-1019(未使用佐剂的二价RSV PreF 三聚体亚单位候选疫苗,基于三叶草生物Trimer-Tag蛋白质三聚体化疫苗研发平台)已获美国食品药品监督管理局(FDA)临床申报(IND)的批准,并且用于评估该候选疫苗重复接种的Ⅰ期临床试验已完成首批受试者入组。

金融界
24 Mar
三叶草生物-B(02197.HK)发布公告,公司RSV候选疫苗SCB-1019(未使用佐剂的二价RSV PreF 三聚体亚单位候选疫苗,基于三叶草生物Trimer-Tag蛋白质三聚体化疫苗研发平台)已获美国食品药品监督管理局(FDA)临床申报(IND)的批准,并且用于评估该候选疫苗重复接种的Ⅰ期临床试验已完成首批受试者入组。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10